Article ID Journal Published Year Pages File Type
6800730 Journal of Psychiatric Research 2015 9 Pages PDF
Abstract
For depressed patients without PPS, SSRIs are likely to be cost-effective in improving remission rates and QALYs compared to TCAs and SNRIs. However, to improve cost-utility in those with comorbid PPS, people need to choose between SSRIs and TCAs according to threshold willingness-to-pay levels. Future research is warranted to clarify the impacts of different pain conditions on the economic evaluations of pharmacological treatments in patients with depression.
Related Topics
Life Sciences Neuroscience Biological Psychiatry
Authors
, , , ,